Abstract:is a ubiquitous, opportunistic human pathogen. Since it often expresses multidrug resistance, it is ranked by the World Health Organization among the top 3 high priority pathogens, for which new treatment options are urgently required. An evaluation of new treatments is usually performed experimentally with one of the canonical laboratory strains (e.g., PAO1 or PA14). However, these two strains are unlikely representative of the strains infecting patients, because they have adapted to laboratory conditions and do not capture the enormous genomic diversity of the species. Here, we characterized the major clone type (mPact) panel. This panel consists of 20 strains, which reflect the genomic diversity of the species, cover all major clone types, and have both patient and environmental origins. We found significant strain variation in distinct responses towards antibiotics and general growth characteristics. Only few of the measured traits are related, and if so, only for specific antibiotics. Moreover, high levels of resistance were only identified for clinical mPact isolates and could be linked to known AMR (antimicrobial resistance) genes in the sequenced genomes. One strain also produced highly unstable AMR, indicating an evolutionary cost to resistance expression. By linking isolation source, growth, and virulence to life history traits, we further identified specific adaptive strategies for individual mPact strains towards either host processes or degradation pathways. Overall, the mPact panel provides a reasonably sized set of distinct strains, enabling in-depth analysis of new treatment designs or evolutionary dynamics in consideration of the species’ genomic diversity.

Letter: Association between terlipressin and multidrug‐resistant organism rectal colonization: Authors' reply

Letter: Association between terlipressin and multi‐drug‐resistant organism rectal colonisation

Terlipressin therapy is associated with increased risk of colonisation with multidrug‐resistant bacteria in patients with decompensated cirrhosis

Editorial: Terlipressin and MDRO colonisation in cirrhosis—Is there a causal link?

Letter: Helicobacter pylori and metabolic syndrome‐related von Willebrand factor and plasminogen activator inhibitor‐1 activity levels for outcome prediction of advanced chronic liver disease: Authors' reply

Reply to Letter to the Editor: Baricitinib and Toxicity is a Rare Occurrence

Letter: improved alanine aminotransferase level in non-cirrhotic and low-viral load chronic hepatitis B patients treated with nucleotide/nucleoside analogues -authors' reply

Letter: Prospective evaluation of patients with non‐cirrhotic portal hypertension—A single centre study. Authors' reply

Letter: hepatocellular carcinoma risk in patients with non‐selective beta blockers—authors' reply

Letter: Critical appraisal of biologic therapy in early ulcerative colitis management—Addressing study limitations and the role of psychological resilience—Authors' reply

Reply to Jaeschke and Ramachandran, "Putative Effects of an Orally Administered Anti-TLR4 Antibody on Gut Microbiota and Acetaminophen Hepatotoxicity in Mice"

Letter: Persisting with persistence—A caution as an outcome measure in inflammatory bowel disease: Authors' reply

Comparative transcriptional profiling of tildipirosin-resistant and sensitive Haemophilus parasuis

Letter: Critical appraisal of biologic therapy in management of early ulcerative colitis—Addressing study limitations and the role of psychological resilience

Letter: Risks of proton pump inhibitor treatment in cirrhotic patients—Authors' reply

Variation in the response to antibiotics and life-history across the major clone type (mPact) panel

Letter: screening for infectious side effects in patients with IBD—the importance and potential of real‐world remote monitoring. Authors' reply

Collateral sensitivity to pleuromutilins in vancomycin-resistant Enterococcus faecium

Letter: Third‐line therapy in acute severe ulcerative colitis, exploring the uncertainty and unanswered questions

Lactobacillus supports Clostridiales to restrict gut colonization by multidrug-resistant Enterobacteriaceae

Outer membrane permeability of mcr-positive bacteria reveals potent synergy of colistin and macromolecular antibiotics against colistin-resistant Acinetobacter baumannii